Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients

Francesca Sabbatini, Alessandra Bandera, Giulio Ferrario, Daria Trabattoni, Giulia Marchetti, Fabio Franzetti, Mario Clerici, Andrea Gori

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Treatment of HIV-infected patients with interleukin-2 (IL-2) produces significant increases in CD4 T cell counts; however an associated qualitative improvement in cells function has yet to be conclusively demonstrated. By measuring mycobacterial killing activity, we evaluated IL-2-mediated functional immune enhancement ex vivo in immunological nonresponders (INRs). Methods and Findings: PBMC from 12 immunological non-responders (INRs) (CD4+

Original languageEnglish
Article numbere14119
JournalPLoS One
Volume5
Issue number11
DOIs
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients'. Together they form a unique fingerprint.

Cite this